[go: up one dir, main page]

GT201700224A - Proteína de unión a rgma y su uso - Google Patents

Proteína de unión a rgma y su uso

Info

Publication number
GT201700224A
GT201700224A GT201700224A GT201700224A GT201700224A GT 201700224 A GT201700224 A GT 201700224A GT 201700224 A GT201700224 A GT 201700224A GT 201700224 A GT201700224 A GT 201700224A GT 201700224 A GT201700224 A GT 201700224A
Authority
GT
Guatemala
Prior art keywords
rgma
binding
time
binding protein
seq
Prior art date
Application number
GT201700224A
Other languages
English (en)
Inventor
Motonori Hashimoto
Toshihide Yamashita
Original Assignee
National Univ Corporation Ch
Mitsubishi Tanabe Pharma Corp
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Univ Corporation Ch, Mitsubishi Tanabe Pharma Corp, Univ Osaka filed Critical National Univ Corporation Ch
Publication of GT201700224A publication Critical patent/GT201700224A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

LA PRESENTE INVENCIÓN TIENE POR OBJETO OBTENER UNA MOLÉCULA GUÍA ANTI-REPELENTE A (RGMA) QUE TENGA UNA ALTA ACTIVIDAD DE UNIÓN Y POCOS EFECTOS SECUNDARIOS QUE SE PUEDAN USAR COMO MEDICAMENTO PARA PREVENIR, TRATAR O PREVENIR LA RECAÍDA DE ENFERMEDADES NEUROLÓGICAS O INMUNOLÓGICAS. EL PROBLEMA SE RESUELVE PROPORCIONANDO UNA PROTEÍNA DE UNIÓN A RGMA AISLADA QUE NO INHIBE LA UNIÓN ENTRE RGMA Y NEOGENINA SINO QUE NEUTRALIZA LA ACTIVIDAD INHIBIDORA DE LA PROLIFERACIÓN DE NEURITAS DE RGMA, PREFERIBLEMENTE PROPORCIONANDO UN ANTICUERPO ANTI-RGMA QUE TIENE REGIONES DETERMINANTES DE COMPLEMENTARIEDAD QUE TIENEN SECUENCIAS DE AMINOÁCIDOS DE SEQ ID NOS: 30-35 O SEQ ID NO: 36-40 EN EL LISTADO DE SECUENCIAS, Y SFG.
GT201700224A 2015-04-28 2017-10-25 Proteína de unión a rgma y su uso GT201700224A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015091095 2015-04-28

Publications (1)

Publication Number Publication Date
GT201700224A true GT201700224A (es) 2019-07-26

Family

ID=57198582

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700224A GT201700224A (es) 2015-04-28 2017-10-25 Proteína de unión a rgma y su uso

Country Status (33)

Country Link
US (3) US10287346B2 (es)
EP (2) EP3584260A1 (es)
JP (7) JP6497760B2 (es)
KR (4) KR102040235B1 (es)
CN (2) CN107531791B (es)
AU (2) AU2016253886B2 (es)
CA (1) CA2983898A1 (es)
CL (1) CL2017002729A1 (es)
CO (1) CO2017011975A2 (es)
CR (2) CR20200517A (es)
CY (1) CY1122569T1 (es)
DK (1) DK3290441T3 (es)
DO (1) DOP2017000248A (es)
ES (1) ES2758480T3 (es)
GT (1) GT201700224A (es)
HR (1) HRP20192099T1 (es)
HU (1) HUE047146T2 (es)
IL (2) IL287291B (es)
LT (1) LT3290441T (es)
MX (2) MX392169B (es)
NZ (2) NZ775384A (es)
PE (2) PE20180251A1 (es)
PH (1) PH12017501941A1 (es)
PL (1) PL3290441T3 (es)
PT (1) PT3290441T (es)
RS (1) RS59847B1 (es)
RU (1) RU2705304C2 (es)
SA (1) SA517390230B1 (es)
SG (1) SG11201708848TA (es)
SI (1) SI3290441T1 (es)
TW (3) TWI732757B (es)
WO (1) WO2016175236A1 (es)
ZA (2) ZA201708047B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531791B (zh) * 2015-04-28 2021-09-07 田边三菱制药株式会社 RGMa结合蛋白质及其使用
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN110637188B (zh) 2017-05-25 2022-07-12 昕诺飞控股有限公司 灯具
EP3821908A4 (en) 2018-07-10 2022-03-30 Mitsubishi Tanabe Pharma Corporation METHOD OF PREVENTING OR TREATING PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING A DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTIC DISORDER IS RECOGNIZED
CN116850291A (zh) * 2018-07-19 2023-10-10 国立大学法人东京大学 Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法
AR120898A1 (es) * 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
MX2022008588A (es) * 2020-01-15 2022-08-10 Univ Osaka Agente profilactico o terapeutico para demencia.
CN114980929B (zh) * 2020-01-15 2024-07-09 国立大学法人大阪大学 糖尿病性自主神经障碍的预防或治疗剂
CN112138146B (zh) * 2020-09-25 2022-08-09 安徽医科大学 Manf蛋白的应用
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
AU2023377201A1 (en) 2022-11-07 2025-06-05 Mitsubishi Tanabe Pharma Corporation Agent for preventing or treating disease associated with accumulation of abnormal protein aggregates

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5565331A (en) 1993-11-12 1996-10-15 The Regents Of The University Of California Nucleic acids encoding neural axon outgrowth modulators
US5747262A (en) 1995-10-16 1998-05-05 The Regents Of The University Of California Neurological drug screens
US5824775A (en) 1996-04-19 1998-10-20 The Regents Of The University Of California Human netrin-1
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
AU735607B2 (en) 1997-08-13 2001-07-12 Yale University Central nervous system axon regeneration
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO2000032746A2 (en) 1998-11-30 2000-06-08 Millennium Pharmaceuticals, Inc. Netrin-like and ependymin-like nucleic acids and polypeptides and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
US20030103945A1 (en) 2001-02-09 2003-06-05 Chen Dong Feng Methods and compositions for stimulating axon regeneration and preventing neuronal cell degeneration
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7319138B2 (en) 2002-04-18 2008-01-15 The General Hospital Corporation Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
US7771952B2 (en) 2002-06-26 2010-08-10 Abott Laboratories Modulators and modulation of the interaction between RGM and Neogenin
US20040199186A1 (en) 2003-04-04 2004-10-07 Kuffler Suzanne Elizabeth Implant to promote axon regeneration across spinal cord and peripheral nerve gaps
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
CN1950108A (zh) * 2004-03-11 2007-04-18 生物线索株式会社 轴突再生促进剂
KR20070015398A (ko) 2004-03-11 2007-02-02 바이오클루즈 가부시키가이샤 축색 재생 촉진제
EP1773375A1 (en) 2004-07-14 2007-04-18 University of Utah Research Foundation Netrin-related compositions and uses
US20060063208A1 (en) * 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7449442B2 (en) 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
WO2007039256A2 (de) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US20080051319A1 (en) 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
WO2008038599A1 (en) 2006-09-25 2008-04-03 National University Corporation Chiba University Axonal regeneration promoter
EP1906185A1 (en) 2006-09-26 2008-04-02 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DE102008014880A1 (de) 2008-03-12 2009-09-17 Eberhard-Karls-Universität Tübingen Antientzündliches Polypeptid
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN101306193A (zh) 2008-05-15 2008-11-19 复旦大学 人神经突起生长素在制备创伤愈合药物中的应用
EP2282738A4 (en) 2008-06-06 2011-12-21 Childrens Medical Center PROMOTING NEUTRITE GENERATION IN THE ADULT CNS BY CONTROLLING PROTEIN TRANSLATION
JP2010146801A (ja) * 2008-12-17 2010-07-01 Kurita Water Ind Ltd 微生物発電方法及び微生物発電装置
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
US9334323B2 (en) * 2009-12-09 2016-05-10 Mitsubishi Tanabe Pharma Corporation Method of reducing recurrence of multiple sclerosis symptoms in a mammal by administering an anti-repulsive guidance molecule neutralizing antibody
EP3800200A1 (en) * 2011-12-14 2021-04-07 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
SI2807192T1 (sl) 2012-01-27 2018-10-30 AbbVie Deutschland GmbH & Co. KG Sestavki in postopki za diagnozo in zdravljenje bolezni povezanih z degeneracijo nevritov
WO2013113107A1 (en) 2012-02-03 2013-08-08 University Health Network Methods for promoting neuron survival, axonal growth and/or regeneration
GB201203180D0 (en) * 2012-02-24 2012-04-11 Okapi Sciences Nv Compounds for treating parvovirus infection
US20140242043A1 (en) 2013-02-23 2014-08-28 Stemnion, Inc. Methods for preventing or treating optic neuritis
SMT201800503T1 (it) * 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
CN105793284A (zh) 2013-09-17 2016-07-20 大学健康网络(Uhn):技术开发和商业化公司 针对顺式RGMa/再生蛋白相互作用或脂筏的试剂及其在治疗方法中的应用
EP3102939A4 (en) 2014-02-05 2018-02-28 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
CN107531791B (zh) 2015-04-28 2021-09-07 田边三菱制药株式会社 RGMa结合蛋白质及其使用
CN105925578A (zh) 2016-05-30 2016-09-07 东北师范大学 靶向沉默Neogenin的shRNA
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof

Also Published As

Publication number Publication date
LT3290441T (lt) 2020-02-10
DK3290441T3 (da) 2020-01-02
IL287291A (en) 2021-12-01
PL3290441T3 (pl) 2020-05-18
MX392169B (es) 2025-03-21
NZ775372A (en) 2024-12-20
DOP2017000248A (es) 2018-01-31
HUE047146T2 (hu) 2020-04-28
BR112017022994A2 (pt) 2019-11-19
RU2705304C2 (ru) 2019-11-06
TW202328205A (zh) 2023-07-16
US10287346B2 (en) 2019-05-14
HRP20192099T1 (hr) 2020-03-06
KR102613528B1 (ko) 2023-12-12
CR20200517A (es) 2021-01-12
EP3290441A1 (en) 2018-03-07
IL287291B (en) 2022-09-01
IL255293B (en) 2021-10-31
CA2983898A1 (en) 2016-11-03
HK1245808A1 (en) 2018-08-31
PT3290441T (pt) 2019-12-02
KR102451786B1 (ko) 2022-10-05
PE20180251A1 (es) 2018-02-02
CR20170539A (es) 2018-04-20
MX2017013894A (es) 2018-03-01
KR20170138565A (ko) 2017-12-15
JP2023030057A (ja) 2023-03-07
JP2025029166A (ja) 2025-03-05
TWI873350B (zh) 2025-02-21
NZ775384A (en) 2024-12-20
KR20190124350A (ko) 2019-11-04
CO2017011975A2 (es) 2018-02-20
MX2022005565A (es) 2022-06-09
NZ737770A (en) 2024-09-27
CN113801225A (zh) 2021-12-17
CY1122569T1 (el) 2021-01-27
IL255293A0 (en) 2017-12-31
JP7307446B2 (ja) 2023-07-12
ZA201907773B (en) 2021-05-26
AU2016253886A1 (en) 2017-12-14
ZA201708047B (en) 2020-01-29
PH12017501941A1 (en) 2018-03-19
CN107531791A (zh) 2018-01-02
JP2023025285A (ja) 2023-02-21
RU2017135353A (ru) 2019-04-08
EP3290441B1 (en) 2019-10-30
SG11201708848TA (en) 2017-11-29
JP2019141048A (ja) 2019-08-29
TWI732757B (zh) 2021-07-11
RS59847B1 (sr) 2020-02-28
JPWO2016175236A1 (ja) 2018-04-19
CN107531791B (zh) 2021-09-07
TW202138389A (zh) 2021-10-16
SI3290441T1 (sl) 2020-03-31
KR102040235B1 (ko) 2019-11-05
JP6955721B2 (ja) 2021-10-27
WO2016175236A1 (ja) 2016-11-03
CL2017002729A1 (es) 2018-06-08
JP7606196B2 (ja) 2024-12-25
KR20230173734A (ko) 2023-12-27
PE20230381A1 (es) 2023-03-06
EP3584260A1 (en) 2019-12-25
ES2758480T3 (es) 2020-05-05
RU2019134410A (ru) 2020-03-03
TW201710296A (zh) 2017-03-16
US11008388B2 (en) 2021-05-18
JP7306660B2 (ja) 2023-07-11
KR20220140023A (ko) 2022-10-17
AU2016253886B2 (en) 2019-05-16
AU2019210655A1 (en) 2019-08-22
SA517390230B1 (ar) 2021-06-09
JP2021106587A (ja) 2021-07-29
RU2017135353A3 (es) 2019-04-08
US20210277098A1 (en) 2021-09-09
US20180100012A1 (en) 2018-04-12
US20190270799A1 (en) 2019-09-05
TWI873576B (zh) 2025-02-21
JP6497760B2 (ja) 2019-04-10
JP2023120374A (ja) 2023-08-29
EP3290441A4 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
GT201700224A (es) Proteína de unión a rgma y su uso
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
BR112018067731A2 (pt) coagonistas de glucagon e glp-1 para o tratamento de obesidade
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
MX348464B (es) Agente inductor de inmunidad.
BR112022007677A2 (pt) L-asparaginase recombinante
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
MX2016015868A (es) Metodos y composiciones para el tratamiento de trastornos con polipeptidos de folistatina.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MX2015016715A (es) Agonistas del receptor de la vitamina d para tratar enfermedades que afectan a la actividad de cxcl12.
UA118558C2 (uk) Пептидна сполука
BR112013029525A8 (pt) Proteínas de fusão terapêuticas
AR092076A1 (es) Proteinas homodimericas
NZ739568A (en) Glp-1 and use thereof in compositions for treating metabolic diseases
MX381278B (es) Composición para la estimulación ovárica controlada.
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
BR112017025000A2 (pt) tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
PL394618A1 (pl) Przeciwnowotworowe bialko fuzyjne
EA201890163A1 (ru) Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии